Recent advances in the generation of bispecific antibodies for tumor immunotherapy.

摘要: Bispecific antibodies are currently in clinical and preclinical development for the treatment of various cancers. Designed to direct enhance body's immune response specific tumors, bispecific consist a targeting domain (typically an antibody fragment that binds tumor antigen) linked triggering arm is cell-surface molecule capable mediating phagocytic or lytic by macrophages, natural killer cells, T-cells, other effector cells. Recent animal studies have confirmed therapeutic potential antibodies; however, results from trials so far been less promising revealed clear limitations these molecules, such as immunogenicity severe side effects caused mass release inflammatory cytokines. A second generation single-chain hetero-oligomeric-engineered antibodies, has now produced using DNA recombinant technology; may theoretically improve minimize effects, eventually replacing full-length antibodies. Over next few years, several expected enter ultimately emerge new pharmaceutical products. This review briefly summarizes major trends therapy, describes rationale novel molecules.